1st, 2nd, 3Rd OctObeR 2012Cité Internationale Universitaire of Paris, France

3rd editiOn

InnovatIon Days 2012 HIgHlIgHts Excellent early-stage networking opportunities

selected Biotechnology companies presentations

Interactive workshops and panels featuring life sciences experts

International exhibition of major new products and solutions

Cité Internationale Universitaire27 Boulevard Jourdan • 75014 Paris

Pre l iminar y Program

p r e l i m i n a r y p r O G r a m m O n D a y , O C T O B e r 1 s T , 2 0 1 2

9:00 Registration and exhibition open continental breakfast

9:20 - 9:30 Welcome and opening remarks

9:30 - 10:15 Keynote opening address

the Place of Open innovation in the biotechnology and Healthcare sector in 2012: Facts and challenges

the industry is clearly grappling with a significant need to change its innovation model and engage in new way of thinking. If internal R&D and external alliances remain the leading source of innovation, there is an emerging trend towards open Innovation. the concept is being seen as an effective way to stimulate new ideas and to innovate more cost effectively.

Can open Innovation really solve pharma’s productivity crisis?this high-level presentation will deliver views from various stakeholders in the innovation process in order to debate the reality of the open Innovation Concept:

the open Innovation agenda and evidence: Has it really worked so far for Pharma? Is it making any difference in the market? overcoming the challenges inherent in open Innovation: Process coordination, Management of Intellectual Property, Research Costs

How Pharma are applying open Innovation in their business model?

10:15 - 11:00 Plenary session

Fostering early-stage Partnership Among Pharma and Academia

Driven in part by the dearth of vC available for early-stage start-ups and competition for late-stage in-licensing candidates, pharma companies are turning to academic institutions to foster early stage partnerships. these collaborations can be a way to access technologies and engage with talent already at university level. Within the academic institutions, the more commercially minded see these partnerships as a way to move their programs and technologies from the bench into the clinic more efficiently.

How do Pharma and academia overcome conflicting core values, rights to IP, and co-mingling of funds to successfully manage the alliance?

Is there a new drug development business model evolving that reduces the need for venture capital?

this panel will explore the growing importance of academia to the future of Pharma’s R&D pipelines.

11:00 - 11:30 networking break

11:30 - 12:45 tHeRAPeutic insigHt: FOcus On cARdiOVAscuLAR

TherapeuTiC insiGhT:"therapeutic Insight" is a new forum of Innovation Days dedicated to industry executives to gain an enriched understanding of transformational challenges emerging across the industry and within the scientific, clinical and commercial spectra of selected diseases and technological areas. therapeutic insight sessions will provide an overview of development and regulatory issues, as well as market dynamics and business development challenges.

p r e l i m i n a r y p r O G r a m m O n D a y , O C T O B e r 1 s T , 2 0 1 2

12:45 - 2:00 Lunch

2:00 - 3:30 tHeRAPeutic insigHt: FOcus On inFectiOus diseAses

3:30 - 4:00 networking break

4:00 - 5:00 Keynote session

european bioclusters organizations: sparring partners for innovation

globalization of research and Innovation and global competition are putting a new emphasis on the role of regional clusters and further development.

this session will address the way that clusters foster Innovation in life sciences sector thanks to:

Close collaborations between academia and industry access to national investors talented individuals governmental support

through testimonials, the clusters representatives will highlight the key success ingredients that bring fruitful ecosystem to their members and particularly to young innovative companies.

5:00 - 6:00 Keynote session

Addressing biotech funding difficultiesWhat makes a biotech company successful?

For young biotechs, attracting seed and early-stage funding has become increasingly difficult in recent years although anecdotal signs of recovery are beginning to emerge.

However it is still possible to identify certain characteristics that make some biotech business models more likely to succeed than others.

this panel will address the strategies being employed by biotech CEos and early-stage investors to ensure an adequately funded R&D pipeline.

trying to figure out the best biotech business model? this session is a great place for biotechnology companies to meet and share ideas.

6:00 exhibit Hall Hospitality Reception

p r e l i m i n a r y p r O G r a m T u e s D a y , O C T O B e r 2 n D , 2 0 1 2

9:30 - 10:30 Keynote session

Human and social science perspectives on biotechnologiesOrganizational solutions and drivers for innovation

Human resources management is an essential criteria for success in a rapidly changing world of scientific understanding and marketplace evolution. However, the biotech industry generally does not feel that the capital produced by its employees is the most precious resource. the social organization, the enterprise culture and its values are key factors of success to translate science and innovation into medicines that make a difference.

this presentation will explore successful initiatives focused on the establishment of a highly functional culture and organization.

setting-up your organization to ensure an environment of innovation, sharing transversally across the organization and establishing a toolkit of practices that work.

10:30 - 11:30 closing Panel discussion

Market Access and innovationReverse drug development process to meet changing payer requirements?

In order to launch a successful product, reimbursement needs to be taken into account far earlier in the development lifecycle than in the past.this session will focus on the R&D’s role in developing products with a greater probability of market access:

Developing a disease area strategy for an unmet clinical or economic need, Understanding the willingness of the public or private payer to cover a drug (cost/ differentiation),

Insights for early feedback on the feasibility of market access for a developing product.

attractiveness to payers, what does this really mean? this panel will deliver provocative views on attempts to formulate recipes to develop a go-to-market strategy.

11:30 - 12:00 networking break

12:00 - 12:45 tHeRAPeutic insigHt: FOcus On OncOLOgY & PeRsOnALized Medicine

12:45 - 2:00 Lunch

p r e l i m i n a r y p r O G r a m T u e s D a y , O C T O B e r 2 n D , 2 0 1 2

2:00 - 3:00 Presenting session: innovation Prize Finalists

Universal Biotech Innovation Prize is aiming to acknowledge innovative talent and the development of new processes or products in the biotechnology industries sector.

Innovation Prize is intended to International project owners within young biotech Companies and to academic members working in research. this grant rewards the best innovation within the three following areas: Preventive & curative therapies, Medical devices and technological tools.

3:00 - 3:30 innovation Prize ceremony

3:30 - 4:00 closing networking break

tecHnOLOgicALtOOLs

MedicALdeVicesPReVentiVe

And cuRRAtiVe

tHeRAPies

1st, 2nd & 3Rd OctObeR 2012Cité Internationale Universitaire of Paris, France

universal medica Group106 Bureaux de la Colline92213 saint-Cloud CedexFRanCE

+33 (0) 1 41 12 27 77+33 (0) 1 41 12 27 83

contact@universalmedica.com

www.lifescience-outlook.com/innovationdays2012/homepage